<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Priority surgery recommendations based on different guidelines</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Malignancy</th>
    <th>ACS guidelines* [
     <xref ref-type="bibr" rid="CR28">28</xref>]
    </th>
    <th>SSO guidelines [
     <xref ref-type="bibr" rid="CR29">29</xref>]
    </th>
    <th>IASO guidelines [
     <xref ref-type="bibr" rid="CR30">30</xref>]
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Breast</td>
    <td>
     <p>Post NACT IDC,</p>
     <p>HER2-positive cases,</p>
     <p>Tumours with discordant biopsy recurrent tumours.</p>
    </td>
    <td>
     <p>Progressive disease on NACT</p>
     <p>Angiosarcoma</p>
     <p>Malignant phyllodes tumour.</p>
    </td>
    <td>
     <p>Poor responders to NACT</p>
     <p>Malignant phyllodes</p>
     <p>Sarcomas</p>
     <p>Patients where systemic therapy cannot be offered.</p>
    </td>
   </tr>
   <tr>
    <td>Thoracic</td>
    <td>
     <p>Oesophageal cancer</p>
     <p>Lung cancer &gt; 2 cm, post NACT</p>
     <p>High-grade chest wall tumours</p>
     <p>Symptomatic mediastinal tumours</p>
     <p>Staging mediastinoscopy</p>
    </td>
    <td>–</td>
    <td>
     <p>Lung cancer</p>
     <p>Post NACT oesophageal cancer</p>
    </td>
   </tr>
   <tr>
    <td>HPB</td>
    <td>–</td>
    <td>Curative intent stomach pancreas, periampullary and duodenal cancer cases</td>
    <td>
     <p>Pancreas/periampullary cancer</p>
     <p>Gall bladder cancer</p>
     <p>Post NACT stomach cancer</p>
    </td>
   </tr>
   <tr>
    <td>Colorectal</td>
    <td>
     <p>Colonic cancer</p>
     <p>Nearly obstructing/bleeding tumours</p>
     <p>Poor responders to NACTRT</p>
    </td>
    <td>Curative intent colonic cancer cases</td>
    <td>Colonic cancer</td>
   </tr>
   <tr>
    <td>Gynaecological</td>
    <td>
     <p>Ovarian cancer</p>
     <p>Endometrial cancer</p>
     <p>Cervical cancer</p>
     <p>Gestational trophoblastic tumours</p>
    </td>
    <td>–</td>
    <td>Early cervical cancer</td>
   </tr>
   <tr>
    <td>Soft tissue</td>
    <td>–</td>
    <td>Non-metastatic STS</td>
    <td>High-grade sarcomas</td>
   </tr>
   <tr>
    <td>Urological</td>
    <td>–</td>
    <td>–</td>
    <td>Orchiectomy for testicular cancer</td>
   </tr>
   <tr>
    <td>Head Neck</td>
    <td>–</td>
    <td>–</td>
    <td>T1 and T2 lesions which can be operated with minimal hospitalisation, aggressive thyroid cancers and refractory hyperparathyroidism</td>
   </tr>
   <tr>
    <td colspan="2">FHNO guidelines for head neck malignancies</td>
    <td colspan="2">EAU Guidelines for urological malignancies [
     <xref ref-type="bibr" rid="CR14">14</xref>]
    </td>
   </tr>
   <tr>
    <td colspan="2">
     <p>Airway obstruction</p>
     <p>Day care surgery and surgery for early lesions</p>
    </td>
    <td colspan="2">
     <p>MIBC</p>
     <p>Testicular cancer (orchiectomy)</p>
     <p>Post NACT RPLND</p>
     <p>cT3+ renal cancer</p>
     <p>High-grade UTUC</p>
     <p>ACC &gt; 6 cm</p>
     <p>Penile/urethral cancer</p>
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>ACS</italic> American College of Surgeons, 
   <italic>SSO</italic> Society of Surgical Oncology, 
   <italic>IASO</italic> Indian Association of Surgical Oncology, 
   <italic>FHNO</italic> Federation of Head Neck Oncology, 
   <italic>EAU</italic> European Association of Urology, 
   <italic>HPB</italic> hepato-pancreato-biliary, 
   <italic>NACT</italic> neoadjuvant chemotherapy, 
   <italic>IDC</italic> infiltrating ductal carcinoma, 
   <italic>NACTRT</italic> neoadjuvant chemoradiation, 
   <italic>STS</italic> soft tissue sarcoma, 
   <italic>MIBC</italic> muscle invasive bladder cancer, 
   <italic>RPLND</italic> retroperitoneal lymph node dissection, 
   <italic>UTUC</italic> upper tract urothelial carcinoma, 
   <italic>ACC</italic> adrenocortical carcinoma
  </p>
  <p>*Phase 1 recommendations where hospital resources are not exhausted, available ICU beds and COVID trajectory not in rapid escalation phase</p>
 </table-wrap-foot>
</table-wrap>
